KRYS

Krystal Biotech, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

KRYSKrystal Biotech, Inc.
0Calm
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Signing up patientsPhase 1/2250 patientsMain results: Feb 2027
KRYSKrystal Biotech, Inc.
0Calm
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Signing up patientsPhase 1/2240 patientsMain results: Jul 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

58 sales (8 not pre-planned) · 0 purchases

Krishnan SumaPresident, R&D · Sep 4, 2026Sold 520 sharesabout $184 thousand · pre-planned
Krishnan SumaPresident, R&D · Sep 4, 2026Sold 2,006 sharesabout $713 thousand · pre-planned
Krishnan SumaPresident, R&D · Sep 4, 2026Sold 3,267 sharesabout $1.2 million · pre-planned
Krishnan SumaPresident, R&D · Sep 4, 2026Sold 3,962 sharesabout $1.4 million · pre-planned
Krishnan SumaPresident, R&D · Sep 4, 2026Sold 3,180 sharesabout $1.1 million · pre-planned
Krishnan SumaPresident, R&D · Sep 4, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.